Protective Effects of Anti-IL17 on Acute Lung Injury Induced by LPS in Mice
Carregando...
Citações na Scopus
44
Tipo de produção
article
Data de publicação
2018
Editora
FRONTIERS MEDIA SA
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
SANTANA, Fernanda Paula Roncon
CRUZ, Maysa Mariana
ALONSO-VALE, Maria Isabel Cardoso
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
FRONTIERS IN PHARMACOLOGY, v.9, article ID 1021, 15p, 2018
Resumo
Introduction: T helper 17 (Th17) has been implicated in a variety of inflammatory lung and immune system diseases. However, little is known about the expression and biological role of IL-17 in acute lung injury (ALI).We investigated the mechanisms involved in the effect of anti-IL17 in a model of lipopolysaccharide (LPS)-induced acute lung injury (ALI) in mice. Methods: Mice were pre-treated with anti-IL17, 1h before saline/LPS intratracheal administration alongside non-treated controls and levels of exhaled nitric oxide (eNO), cytokine expression, extracellular matrix remodeling and oxidative stress, as well as immune cell counts in bronchoalveolar lavage fluid (BALF), and respiratory mechanics were assessed in lung tissue. Results: LPS instillation led to an increase in multiple cytokines, proteases, nuclear factor-kappa B, and Forkhead box P3 (FOXP3), eNO and regulators of the actomyosin cytoskeleton, the number of CD4+ and iNOS-positive cells as well as the number of neutrophils and macrophages in BALF, resistance and elastance of the respiratory system, ARG-1 gene expression, collagen fibers, and actin and 8-iso-PGF2 alpha volume fractions. Pre-treatment with anti-IL17 led to a significant reduction in the level of all assessed factors. Conclusions: Anti-IL17 can protect the lungs from the inflammatory effects of LPS-induced ALI, primarily mediated by the reduced expression of cytokines and oxidative stress. This suggests that further studies using anti-IL17 in a treatment regime would be highly worthwhile.
Palavras-chave
acute lung injury, inflammation mediators, interleukin 17, remodeling, oxidative stress
Referências
- Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8
- Aristoteles LRCRB, 2013, BMC PULM MED, V13, DOI 10.1186/1471-2466-13-52
- Barlow JL, 2011, CLIN EXP ALLERGY, V41, P1447, DOI 10.1111/j.1365-2222.2011.03806.x
- Barnes PJ, 2016, J ALLERGY CLIN IMMUN, V138, P16, DOI 10.1016/j.jaci.2016.05.011
- do Carmo MBB, 2016, DEV PSYCHOBIOL, V58, P1076, DOI 10.1002/dev.21441
- Blondonnet R, 2016, DIS MARKERS, DOI 10.1155/2016/3501373
- Boshier Piers R, 2013, J Breath Res, V7, P017118, DOI 10.1088/1752-7155/7/1/017118
- Camargo LD, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01835
- Castillo R L, 2015, Open Respir Med J, V9, P83, DOI 10.2174/1874306401509010083
- Caucheteux SM, 2017, MUCOSAL IMMUNOL, V10, P361, DOI 10.1038/mi.2016.54
- Defert O, 2017, EXPERT OPIN THER PAT, V27, P507, DOI 10.1080/13543776.2017.1272579
- Ding Q, 2017, ONCOTARGET, V8, P93704, DOI 10.18632/oncotarget.21474
- Elfsmark L, 2018, TOXICOL LETT, V282, P1, DOI 10.1016/j.toxlet.2017.10.007
- Erbel C, 2014, J IMMUNOL, V193, P4344, DOI 10.4049/jimmunol.1400181
- French BM, 2018, XENOTRANSPLANTATION, V25, DOI 10.1111/xen.12385
- Gasch M, 2014, MEDIAT INFLAMM, DOI 10.1155/2014/182549
- Ge SW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085461
- Ghoreschi K, 2010, NATURE, V467, P967, DOI 10.1038/nature09447
- GONCALVESDEALBUQUE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/FIMMU.2017.01437
- Gonzalez-Lopez A, 2012, CRIT CARE, V16, DOI 10.1186/cc11224
- Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138
- Hasegawa T, 2017, EUR CYTOKINE NETW, V28, P8, DOI 10.1684/ecn.2017.0390
- Hendrix AY, 2017, PROG MOL BIOL TRANSL, V148, P1, DOI 10.1016/bs.pmbts.2017.04.004
- Hergrueter AH, 2011, AM J PHYSIOL-LUNG C, V300, pL512, DOI 10.1152/ajplung.00023.2011
- Nguyen H, 2013, CARDIOVASC RES, V97, P696, DOI 10.1093/cvr/cvs422
- Hsu D, 2016, INFECT IMMUN, V84, P2410, DOI 10.1128/IAI.00284-16
- Huang GH, 2012, CELL MOL IMMUNOL, V9, P287, DOI 10.1038/cmi.2012.10
- Bittencourt-Mernak MI, 2017, AM J PHYSIOL-LUNG C, V312, pL217, DOI 10.1152/ajplung.00444.2015
- Kaneko-Kawano T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039269
- Lancas T, 2006, J APPL PHYSIOL, V100, P1610, DOI 10.1152/japplphysiol.00828.2005
- Leitinger N, 2001, FASEB J, V15, P1254
- Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156
- Li TJ, 2017, MOL MED REP, V16, P2225, DOI 10.3892/mmr.2017.6837
- Lo CY, 2018, INT J CHRONIC OBSTR, V13, P1135, DOI 10.2147/COPD.S161257
- Martins-Olivera BT, 2016, MEDIAT INFLAMM, DOI 10.1155/2016/5346574
- Mikacenic C, 2016, CRIT CARE MED, V44, P496, DOI 10.1097/CCM.0000000000001409
- Modrykamien Ariel M, 2015, Proc (Bayl Univ Med Cent), V28, P163
- National Institutes of Health, 2011, GUIDE CARE USE LAB A
- O'Dwyer DN, 2016, AM J PHYSIOL-LUNG C, V311, pL590, DOI 10.1152/ajplung.00221.2016
- Pigati PA, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0073-4
- Pinheiro NM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120441
- Possa SS, 2012, AM J PHYSIOL-LUNG C, V303, pL939, DOI 10.1152/ajplung.00034.2012
- Prado CM, 2006, AM J RESP CELL MOL, V35, P457, DOI 10.1165/rcmb.2005-0391OC
- Prado Carla M, 2011, ISRN Allergy, V2011, P832560, DOI 10.5402/2011/832560
- Prause O, 2004, THORAX, V59, P313, DOI 10.1136/thx.2003.008854
- RighettI RF, 2014, RESP PHYSIOL NEUROBI, V192, P134, DOI 10.1016/j.resp.2013.12.012
- Riva DR, 2008, CRIT CARE MED, V36, P1900, DOI 10.1097/CCM.0b013e3181760e5d
- Rosadini CV, 2017, CURR OPIN IMMUNOL, V44, P14, DOI 10.1016/j.coi.2016.10.005
- Saddy F, 2010, INTENS CARE MED, V36, P1417, DOI 10.1007/s00134-010-1808-6
- Sakaguchi R, 2016, INT IMMUNOL, V28, P233, DOI 10.1093/intimm/dxv070
- Scholz H, 2003, CARDIOVASC RES, V59, P945, DOI 10.1016/S0008-6363(03)00538-8
- Sharanek A, 2016, SCI REP-UK, V6, DOI 10.1038/srep24709
- Theodoro OA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020403
- Vieira RP, 2007, AM J RESP CRIT CARE, V176, P871, DOI 10.1164/rccm.200610-1567OC
- Villegas L, 2014, J PULM RESP MED, V4, P194, DOI 10.4172/2161-105X.1000194
- WEIBEL ER, 1963, LAB INVEST, V12, P131
- WEIBEL ER, 1979, AM J ROENTGENOL, V133, P1020, DOI 10.2214/ajr.133.6.1021
- Witter AR, 2016, J IMMUNOL, V197, P1557, DOI 10.4049/jimmunol.1600599
- Xu H, 2018, CELL RES, V28, P139, DOI 10.1038/cr.2017.156
- Yanagisawa H, 2017, AM J PHYSIOL-LUNG C, V312, pL122, DOI 10.1152/ajplung.00301.2016
- Zhao GM, 2017, INT IMMUNOPHARMACOL, V46, P80, DOI 10.1016/j.intimp.2017.02.017
- Zizzo G, 2013, J IMMUNOL, V190, P5237, DOI 10.4049/jimmunol.1203017